News and Events:
On October 2, 2012, the United States Patent and Trademark Office awarded Prospect Biosystems, Inc. a U.S. Patent (number 8,278,118) for a Method for the Fractionation and Separation of Particles by Step-wise Gradient Density Extraction. This patent is the first of a larger patent family and covers a method or system to identify a ratio of biomarkers from different fractions of a sample homogenate or lysate. This technology provides a powerful biology-based tool for the statistical evaluation of potential biomarkers. Additionally, oncologists now will have a unique opportunity for real-time molecular pathology in determination of clean margins during cancer surgery.
Prospect Biosystems, Inc. engages in the development, manufacturing, and marketing of instrumentation, reagents, consumables, and assays for bioanalytical research and molecular pathology. Prospect’s proprietary Edge™ technology provides a powerful tool to enhance and accelerate life sciences research, pharmaceutical product development, clinical and molecular diagnostics and pathology.
Edge™ platform is a breakthrough bioanalytical fractionation and separation technology that allows scientists, researchers, medical experts, including physicians and surgeons, involved in:
Prospect ... “Outlook for future success”